JAZZ
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Jazz Pharmaceuticals completed its acquisition of Actio BiosciencesSep 15, 2026
- Ziihera plus chemotherapy demonstrated a statistically significant overall survival benefit versus trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinomaAug 31, 2026
- The U.S. FDA approved Ziihera with or without tislelizumab plus chemotherapy for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinomaAug 26, 2026
- Jazz Pharmaceuticals and AbCellera entered a collaboration to develop next-generation T-cell engaging multispecific antibodiesJun 17, 2026
- Jazz Pharmaceuticals received FDA acceptance and Priority Review for supplemental BLA of Ziihera combinations in first-line HER2+ advanced or metastatic GEAApr 27, 2026